Skip to main content

Table 5 Multivariate analysis estimating risk of haemoglobin drop from baseline to ≥1 g/dL during different post-treatment follow-up visits

From: Delayed anemia assessment in patients treated with oral artemisinin derivatives for uncomplicated malaria: a pooled analysis of clinical trials data from Mali

 

Day 7 (2,657)

Day 14 (n=4,638)

Day 28 (n=4,082)

 

OR* (95% CI)

p

OR* (95% CI)

p

OR* (95% CI)

p

Covariates**

      

AL

0.82 (0.58-1.17)

0.27

1.03 (0.82-1.30)

0.81

1.10 (0.82-1.48)

0.52

AS+partners

1.15 (0.95-1.39)

0.16

0.93 (0.75-1.14)

0.47

1.0 (0.77-1.29)

0.99

AS

1.69 (1.31-2.18)

<0.001

0.97 (0.71-1.32)

0.84

1.01 (0.68-1.50)

0.95

<5 years old

0.90 (0.76-1.06)

0.21

0.79 (0.68-0.92)

0.003

0.72 (0.60-0.88)

0.001

P. f. day 0

1.56 (1.33-1.83

<0.001

1.60 (1.38-1.87)

<0.001

1.02 (0.85-1.23)

0.81

Treat fail

1.77 (1.24-2.55)

0.002

1.49 (1.14-1.94)

0.003

1.67 (1.32-2.11)

<0.001

  1. Note: *OR is the odds ratio obtained from generalized linear and latent mixed model with binomial family using site as random effect;
  2. **Covariates references were: CQ, AQ, SP for day 7 and CQ, AQ, SP and SP-AQ for day 14 and day 28 for treatment, the age ≥5 years old for the age group, the 28-day cured parasite outcome after treatment for the treatment failure (Treat fail) outcome, the baseline parasite density was log transformed and treated as continuous variable; AS + partners were: AS-AQ, AS-SP, AS-PYR for day 7, AS-AQ, AS-SP, AS-MEF for day 14 and AS-AQ, AS-SP, AS-PYR, AS-SMP and AS-MEF for day 28.
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us